<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antiribosomal P protein antibodies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antiribosomal P protein antibodies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antiribosomal P protein antibodies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald B Bloch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert H Shmerling, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoantibodies directed against three phosphorylated protein ("P") components of ribosomes are present in a minority of patients with systemic lupus erythematosus (SLE) and are highly specific for this disease. Some studies have suggested that these antibodies may serve as markers for specific disease manifestations, including central nervous system (CNS) disease and hepatitis, but other studies have not confirmed these associations. (See
         <a class="local">
          'Associations with specific manifestations of SLE'
         </a>
         below.)
        </p>
        <p>
         The specificity, clinical associations, and utility of measuring antiribosomal P antibodies are discussed here. An overview of antinuclear antibodies and the approach to the diagnosis of CNS disease in SLE are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1822.html" rel="external">
          "Measurement and clinical significance of antinuclear antibodies"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Attribution of a clinical syndrome to SLE'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANTIBODIES TO RIBOSOMAL P PROTEINS
         </span>
        </p>
        <p class="headingAnchor" id="H17463419">
         <span class="h2">
          Antigen specificity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The targets of antiribosomal antibodies found in the sera of some patients with systemic lupus erythematosus (SLE) are three highly conserved phosphorylated proteins ("P" proteins) located on the 60S subunit of ribosomes [
         <a href="#rid1">
          1,2
         </a>
         ]. The P proteins, which exhibit molecular weights of 35, 19, and 17 kD, are designated P0, P1, and P2, respectively. The immunodominant epitope in patients with SLE is a shared sequence at the carboxy (C)-termini of the P proteins [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
         In their native form, the ribosomal P antigens form a pentamer consisting of one copy of P0 and two copies each of P1 and P2. This complex interacts with the 28S ribosomal RNA molecule to form the ribosomal stalk, including a guanosine triphosphatase (GTPase) domain involved in the elongation step of protein translation [
         <a href="#rid6">
          6
         </a>
         ]. Monoclonal antibodies to P proteins inhibit binding of elongation factor (EF)-1 alpha and EF-2 to ribosomes and inhibit protein synthesis [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         P proteins were initially identified on ribosomes in the cytoplasm [
         <a href="#rid9">
          9
         </a>
         ]; subsequent studies have also detected epitopes recognized by antiribosomal P protein antibodies on the surface of neuronal, hepatoma, and activated T cells in vitro [
         <a href="#rid10">
          10,11
         </a>
         ]. The binding of antibodies to these proteins on cell surfaces could have pathogenic significance, given evidence that such antibodies can be internalized, resulting in cellular dysfunction [
         <a href="#rid6">
          6,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17463426">
         <span class="h2">
          Antibody detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies to ribosomal P proteins produce a finely speckled cytoplasmic staining pattern on a human epithelioma cell, type 2 (HEp-2) cell substrate using indirect immunofluorescence (
         <a class="graphic graphic_picture graphicRef59670" href="/z/d/graphic/59670.html" rel="external">
          picture 1
         </a>
         ). However, the sensitivity of indirect immunofluorescence for the detection of antiribosome P antibodies is less than 30 percent compared with commercially available, solid phase assays. In clinical practice, antiribosome P antibodies may be detected by immunoblot, enzyme-linked immunosorbent assay (ELISA), line immunoassay, or addressable laser bead assay. In these assays, antibodies are detected using purified native or recombinant antigen, synthetic peptides, or a combination of these antigenic targets. In some assays, a 22-amino acid peptide, which is shared by the three ribosomal P proteins and is the major autoantigenic epitope, is used to replace the full-length protein [
         <a href="#rid3">
          3
         </a>
         ]. This peptide-based ELISA has been reported to provide the greatest discrimination between patients with SLE and controls [
         <a href="#rid13">
          13,14
         </a>
         ]. However, it is possible that the lack of full-length ribosome P proteins decreases the sensitivity of some solid phase assays.
        </p>
        <p>
         There are at least nine commercially available assays to detect antiribosome P antibodies: six ELISAs, one line immunoassay, and two addressable laser bead assays. The specificity and sensitivity of antibodies directed against ribosome P using these assays range from 10 to 25 percent (sensitivity) and 95 to 100 percent (specificity) [
         <a href="#rid15">
          15
         </a>
         ]. Unfortunately, international standardization of assays to detect antibodies directed against ribosomal proteins has not yet been achieved, and there is no "gold standard" approach to detecting these antibodies.
        </p>
        <p class="headingAnchor" id="H3232405751">
         <span class="h1">
          DISEASE ASSOCIATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical significance of antiribosomal phosphorylated protein (P) antibodies is their specificity for the diagnosis of systemic lupus erythematosus (SLE) [
         <a href="#rid16">
          16-18
         </a>
         ]. As indicated above, these antibodies have not been found in normal controls [
         <a href="#rid13">
          13,17,19
         </a>
         ] and are rare in patients with other autoimmune diseases [
         <a href="#rid13">
          13,20
         </a>
         ]. In a retrospective study of 487 SLE patients, the prevalence of antiribosomal P, anti-Sm, and anti-double-stranded DNA (anti-dsDNA) antibodies was 31.6, 20.7, and 45 percent, respectively [
         <a href="#rid21">
          21
         </a>
         ]. It was reported that 27.9 percent of SLE patients had antiribosomal P antibodies and were negative for anti-Sm and anti-dsDNA antibodies. Antiribosomal P antibodies were considered to be most valuable in the diagnosis of SLE when other, specific autoantibodies are not detected.
        </p>
        <p>
         As might be expected, given the variety of tests used to detect antiribosome P antibodies, the reported prevalence of antiribosomal P antibodies among patients with SLE is quite variable. Antiribosomal P antibodies were initially detected in 10 to 20 percent of patients with SLE [
         <a href="#rid10">
          10,16,17,22
         </a>
         ]; however, other studies including adult SLE patients from China and Japan and children from the United States, Argentina, and Brazil have reported higher rates of prevalence (25 to 50 percent) [
         <a href="#rid20">
          20,23-26
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An international study involving 11 centers, 947 patients with SLE, and 1113 controls used a mixture of three recombinant ribosomal P polypeptides as the antigenic target in an enzyme-linked immunosorbent assay (ELISA); the sensitivity and specificity of antiribosomal P antibodies for SLE were 21 and 99 percent, respectively [
         <a href="#rid23">
          23
         </a>
         ]. The prevalence of antiribosomal P antibodies in patients with SLE at each individual center ranged from a high of 35 percent for patients from China to 8 percent for patients from Canada. None of 208 normal sera used as controls tested positive. The disease controls with positive tests included patients with rheumatoid arthritis (RA; 3 of 284 patients), patients with systemic sclerosis (SSc; 2 of 131), and one patient each with hepatitis C, mixed connective tissue disease (MCTD), and polymyositis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another multicenter study, which employed an ELISA using the C22 epitope as the antigenic target, showed similar sensitivity and specificity for SLE (23 and 99 percent, respectively) [
         <a href="#rid13">
          13
         </a>
         ]. Testing was negative in healthy blood donors and in patients with RA or Sjögren's disease (n = 135, 60, and 26, respectively). One patient each with MCTD, limited cutaneous SSc, ulcerative colitis, and polymyalgia rheumatica tested positive.
        </p>
        <p>
        </p>
        <p>
         Several factors may be responsible for the variability of the prevalence of antiribosomal P antibodies in different populations of SLE patients, including differences in the techniques used to detect antibodies, variable ethnic or genetic composition of populations, and differences in regional practice and in patient selection [
         <a href="#rid15">
          15,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5856066">
         <span class="h1">
          ASSOCIATIONS WITH SPECIFIC MANIFESTATIONS OF SLE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential association between the presence of antiribosomal phosphorylated protein (P) antibodies and specific manifestations of systemic lupus erythematosus (SLE) is highly controversial. Antiribosomal P antibodies have been associated in different studies with SLE involving the central nervous system (CNS), liver, kidney, and skin. By contrast, other studies have not demonstrated such associations. Some studies have also suggested that these antibodies are markers for SLE disease activity.
        </p>
        <p>
         The same factors that appear to account for differences in the prevalence of antiribosomal P antibodies among different groups of patients with SLE are likely to result in the variability in the associations with different clinical manifestations. Additionally, small sample sizes in many of the positive studies described below and differences in methods for detection of antibody may also be important.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Central nervous system disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the variable results from several studies, testing for antiribosomal P antibodies has limited diagnostic value for neuropsychiatric SLE and is not helpful in differentiating between clinical subtypes of neuropsychiatric SLE.
        </p>
        <p>
         Some studies have suggested an association between the presence of antiribosomal P antibodies and neuropsychiatric manifestations of SLE, particularly psychosis [
         <a href="#rid17">
          17,19,20,27,28
         </a>
         ]; however, other studies do not support such an association [
         <a href="#rid13">
          13,22,29,30
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lack of diagnostic utility of antiribosomal P antibodies for neuropsychiatric SLE is supported by a meta-analysis of observational data from 1537 patients with SLE from 14 centers in Europe, Asia, and South America [
         <a href="#rid31">
          31
         </a>
         ]. The presence of antiribosomal P antibodies had an overall sensitivity and specificity for lupus of 26 and 80 percent, respectively. The sensitivity and specificity were similar for psychosis, mood disorder, or both (27 and 80 percent) and for other diffuse manifestations (24 and 80 percent). Positive testing did not distinguish between different manifestations of neuropsychiatric SLE, and results between different centers showed significant heterogeneity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study involving 116 patients with SLE, no association between the presence of antiribosomal P antibodies and neuropsychiatric SLE was observed; the sensitivity and specificity of antiribosomal P antibodies for neuropsychiatric disease were 21 and 13 percent, respectively [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Liver disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         An association between antiribosomal P antibodies and SLE-associated liver disease was suggested in several reports, including two small case-control studies, following an initial case report of a patient with lupus in whom antiribosomal P antibodies were produced soon after the development of chronic active hepatitis [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study found a higher number of patients with SLE-related liver disease among 20 patients with SLE and antiribosomal P antibodies than among controls with SLE but without such antibodies (7 of 20 patients versus 1 of 20 patients) [
         <a href="#rid33">
          33
         </a>
         ]. Antibodies to ribosomal P were not found in the sera of 59 patients with autoimmune liver diseases, including chronic active hepatitis, primary biliary cholangitis (previously referred to as "primary biliary cirrhosis"), and sclerosing cholangitis in the absence of lupus, suggesting that the autoantibodies were not the result of immune-related hepatic injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report found a higher number of patients with antiribosomal P antibodies among patients with SLE-related hepatitis compared with a control group of SLE patients without liver disease (6 of 6 patients versus 2 of 20 patients) [
         <a href="#rid34">
          34
         </a>
         ]. Hepatitis was present in only 3 percent of the patients in the large lupus cohort, from which most of the patients for the study were drawn.
        </p>
        <p>
        </p>
        <p>
         Several large studies have had too few patients with liver disease to draw any firm conclusions regarding this association, and further studies are required for confirmation [
         <a href="#rid13">
          13,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Renal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiribosomal P antibodies have been associated with the presence and activity of lupus nephritis in several, mostly small, studies [
         <a href="#rid33">
          33,36-38
         </a>
         ]; however, other reports have failed to confirm these observations [
         <a href="#rid17">
          17,22,30,35
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An international multicenter study of 333 patients with SLE and 397 controls found no association between antiribosomal P antibodies and the presence of nephritis [
         <a href="#rid13">
          13
         </a>
         ]. A single-center study from North Africa of 200 patients with SLE and 130 controls also found no association with renal disease [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study found a higher number of patients with SLE-related renal disease among 20 patients with SLE and antiribosomal P antibodies than among controls with SLE but without such antibodies (14 of 20 patients versus 4 of 20 patients) [
         <a href="#rid33">
          33
         </a>
         ]. In other studies, levels of antiribosomal P antibodies fluctuated with the activity of renal disease and correlated with the anti-double-stranded DNA (anti-dsDNA) antibody titer [
         <a href="#rid36">
          36,37
         </a>
         ]. In one report, antiribosomal P antibodies were primarily associated with membranous lupus [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Skin disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous manifestations of SLE have been associated with antiribosomal P antibodies in several studies [
         <a href="#rid22">
          22,30,39
         </a>
         ]. As an example, in an Italian multicenter study of 149 consecutively seen patients with SLE, there was a significantly higher prevalence of both malar and discoid rashes among antibody-positive compared with antibody-negative patients at the time of the evaluation (61 versus 31 percent and 17 versus 2 percent, respectively) [
         <a href="#rid30">
          30
         </a>
         ]. By contrast, other studies have not found this association [
         <a href="#rid13">
          13,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H366645511">
         <span class="h2">
          Other associations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other associations have been reported in some studies but not others [
         <a href="#rid6">
          6,40
         </a>
         ], including associations with younger age [
         <a href="#rid13">
          13
         </a>
         ], arthritis [
         <a href="#rid35">
          35
         </a>
         ], increased disease activity [
         <a href="#rid35">
          35,37
         </a>
         ], low levels of complement C3 or C4 [
         <a href="#rid13">
          13
         </a>
         ], and increased prevalence of anti-dsDNA [
         <a href="#rid3">
          3
         </a>
         ] and anticardiolipin antibodies [
         <a href="#rid30">
          30,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          CLINICAL UTILITY OF ANTIRIBOSOMAL P ANTIBODIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing for antiribosomal phosphorylated protein (P) antibodies is most useful in helping to establish the diagnosis of systemic lupus erythematosus (SLE) in settings in which the diagnosis is uncertain; a role in diagnosis similar to that of anti-double-stranded DNA (anti-dsDNA) and anti-Sm antibodies is supported by the high specificity of these antibodies for SLE, while recognizing their mild to moderate sensitivity. (See
         <a class="local">
          'Disease associations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'
         </a>
         .)
        </p>
        <p>
         Testing for antiribosomal P antibodies is generally not useful in the diagnosis or management of neuropsychiatric SLE, given the broad range of results for sensitivity and specificity that has been observed between patients in various studies. (See
         <a class="local">
          'Associations with specific manifestations of SLE'
         </a>
         above and
         <a class="local">
          'Central nervous system disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Attribution of a clinical syndrome to SLE'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H213548507">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118881.html" rel="external">
          "Society guideline links: Antinuclear antibodies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H184887">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main targets of antiribosomal phosphorylated protein (P) antibodies found in the sera of some patients with systemic lupus erythematosus (SLE) are three highly conserved phosphorylated proteins located on the 60S subunit of ribosomes. Epitopes recognized by antiribosomal P antibodies are also present on the surfaces of some cells. (See
         <a class="local">
          'Antigen specificity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiribosomal P antibodies produce a finely speckled cytoplasmic staining pattern on a human epithelioma cell, type 2 (HEp-2) cell substrate using indirect immunofluorescence (
         <a class="graphic graphic_picture graphicRef59670" href="/z/d/graphic/59670.html" rel="external">
          picture 1
         </a>
         ). The sensitivity of indirect immunofluorescence for the detection of antiribosomal P antibodies is low. In clinical practice, these antibodies may be detected by immunoblot, enzyme-linked immunosorbent assay (ELISA), line immunoassay, or addressable laser bead assay. (See
         <a class="local">
          'Antibody detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical significance of antiribosomal P antibodies is their specificity for the diagnosis of SLE. These antibodies have not been found in normal controls and are rare in patients with other autoimmune diseases. The reported prevalence of antiribosomal P antibodies among patients with SLE is quite variable. (See
         <a class="local">
          'Disease associations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiribosomal P antibody testing has limited diagnostic value for neuropsychiatric SLE and is not helpful in differentiating clinical subtypes of SLE. Some studies have suggested a strong association between the presence of antiribosomal P antibodies and neuropsychiatric manifestations of SLE, while other studies do not support such an association. (See
         <a class="local">
          'Central nervous system disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various studies have also suggested that these antibodies are markers for SLE disease activity and various clinical or laboratory manifestations of SLE other than neuropsychiatric disease, but contradictory data have also been reported for these associations. (See
         <a class="local">
          'Associations with specific manifestations of SLE'
         </a>
         above and
         <a class="local">
          'Liver disease'
         </a>
         above and
         <a class="local">
          'Renal disease'
         </a>
         above and
         <a class="local">
          'Skin disease'
         </a>
         above and
         <a class="local">
          'Other associations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for antiribosomal P antibodies is most useful in helping to establish the diagnosis of SLE in settings in which the diagnosis is uncertain, given the high specificity but low to moderate sensitivity of these antibodies for SLE. (See
         <a class="local">
          'Clinical utility of antiribosomal P antibodies'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985; 162:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francoeur AM, Peebles CL, Heckman KJ, et al. Identification of ribosomal protein autoantigens. J Immunol 1985; 135:2378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahler M, Kessenbrock K, Raats J, et al. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med (Berl) 2003; 81:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkon K, Skelly S, Parnassa A, et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1986; 83:7419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasler P, Brot N, Weissbach H, et al. The effect of phosphorylation and site-specific mutations in the immunodominant epitope of the human ribosomal P proteins. Clin Immunol Immunopathol 1994; 72:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005; 38:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchiumi T, Traut RR, Kominami R. Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probes. J Biol Chem 1990; 265:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacey DW, Skelly S, Watson T, et al. The inhibition of protein synthesis by IgG containing anti-ribosome P autoantibodies from systemic lupus erythematosus patients. Arch Biochem Biophys 1988; 267:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyachi K, Tan EM. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum 1979; 22:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koren E, Reichlin MW, Koscec M, et al. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992; 89:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirohata S, Itoh K, Nakanishi K. Antiribosomal P protein antibody in human systemic lupus erythematosus is an antilymphocyte antibody that specifically reacts with activated T cells. (abstract) Arthritis Rheum 2000; 43:S240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koscec M, Koren E, Wolfson-Reichlin M, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997; 159:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahler M, Agmon-Levin N, van Liempt M, et al. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatol Int 2012; 32:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahler M, Kessenbrock K, Raats J, Fritzler MJ. Technical and clinical evaluation of anti-ribosomal P protein immunoassays. J Clin Lab Anal 2004; 18:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi MY, FitzPatrick RD, Buhler K, et al. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev 2020; 19:102463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonfa E, Elkon KB. Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 1986; 29:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koffler D, Miller TE, Lahita RG. Studies on the specificity and clinical correlation of antiribosomal antibodies in systemic lupus erythematosus sera. Arthritis Rheum 1979; 22:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato T, Uchiumi T, Ozawa T, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991; 18:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Luo P, Guo T, et al. Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus. Medicine (Baltimore) 2020; 99:e20192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dam A, Nossent H, de Jong J, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol 1991; 18:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006; 13:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nojima Y, Minota S, Yamada A, et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichlin M, Broyles TF, Hubscher O, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valões CC, Molinari BC, Pitta AC, et al. Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients. Lupus 2017; 26:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teh LS, Bedwell AE, Isenberg DA, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992; 51:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koren E, Schnitz W, Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993; 36:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulsey M, Goldstein R, Scully L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddouk S, Marzouk S, Jallouli M, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichlin M, Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 2003; 108:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chindalore V, Neas B, Reichlin M. The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. Clin Immunol Immunopathol 1998; 87:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           do Nascimento AP, Viana Vdos S, Testagrossa Lde A, et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 2006; 54:1568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000; 59:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghirardello A, Doria A, Zampieri S, et al. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 2000; 59:975.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1817 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2410526" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lupus autoantibodies target ribosomal P proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3897374" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Identification of ribosomal protein autoantigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682728" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2429305" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8050201" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effect of phosphorylation and site-specific mutations in the immunodominant epitope of the human ribosomal P proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15804709" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Anti-ribosomal P protein antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1688437" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3196035" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The inhibition of protein synthesis by IgG containing anti-ribosome P autoantibodies from systemic lupus erythematosus patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/103560" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313450" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antiribosomal P protein antibody in human systemic lupus erythematosus is an antilymphocyte antibody that specifically reacts with activated T cells
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9257871" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21140265" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15202113" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Technical and clinical evaluation of anti-ribosomal P protein immunoassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31927088" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3527180" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical and serologic associations of the antiribosomal P protein antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1986591" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/109096" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Studies on the specificity and clinical correlation of antiribosomal antibodies in systemic lupus erythematosus sera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3496538" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Association between lupus psychosis and anti-ribosomal P protein antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1787488" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32443340" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1920307" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16426003" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : International multicenter evaluation of autoantibodies to ribosomal P proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417136" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920016" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28394238" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18311802" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21893582" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1586246" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Antibodies to protein P in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12468814" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16385548" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216426" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7859415" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485202" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19502474" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12865073" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9646839" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645990" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10666163" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17289545" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical and biological aspects of anti-P-ribosomal protein autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11087701" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
